Actively Recruiting
Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA
Led by Thammasat University Hospital · Updated on 2025-04-09
80
Participants Needed
1
Research Sites
60 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this RCT is to compare efficacy between mirogabalin and pregabalin in pain reducing after unilateral primary total knee arthroplasty. The main question\[s\] it aims to answer are: • Does mirogabalin have better pain reduction than pregabalin after unilateral primary total knee arthroplasty. Participants will randomized to mirogabalin or pregabalin group and will take the drug for 6 weeks after TKA. Researchers will compare to pregabalin group to see pain and functional outcomes after TKA.
CONDITIONS
Official Title
Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 50 to 85 years
- Diagnosis of unilateral primary osteoarthritis undergoing primary total knee arthroplasty
- American Society of Anesthesiologists (ASA) physical status classification I to III
You will not qualify if you...
- Glomerular filtration rate (GFR) less than 60
- Allergy to study drugs
- Unable to undergo spinal anesthesia and adductor canal block
- Use of gabapentinoid drugs within 3 months before surgery
- History of previous knee surgery
- Severe liver disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Thammasat University Hospital
Khlong Luang, Changwat Pathum Thani, Thailand, 12120
Actively Recruiting
Research Team
Y
Yot Tanariyakul, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here